Theravance Biopharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Jan '26 Jan 8, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Market Capitalization	964	463	560	755	814	1,137	Upgrade
Market Cap Growth	101.42%	-17.33%	-25.82%	-7.35%	-28.37%	-22.63%	Upgrade
Enterprise Value	676	416	477	320	1,269	1,398	Upgrade
Last Close Price	19.02	9.41	11.24	11.22	11.05	17.77	Upgrade
PE Ratio	32.78	-	-	0.87	-	-	Upgrade
PS Ratio	11.82	7.19	9.75	14.70	14.72	15.82	Upgrade
PB Ratio	4.14	2.64	2.63	1.71	-2.40	-3.74	Upgrade
P/TBV Ratio	4.14	2.64	2.63	1.71	-	-	Upgrade
EV/Sales Ratio	8.41	6.47	8.30	6.23	22.95	19.46	Upgrade
Debt / Equity Ratio	0.19	0.28	0.23	0.12	-1.98	-2.23	Upgrade
Asset Turnover	0.21	0.18	0.12	0.11	0.13	0.16	Upgrade
Quick Ratio	9.30	4.89	4.84	11.99	3.20	2.93	Upgrade
Current Ratio	9.48	5.02	5.39	12.31	4.26	3.18	Upgrade
Return on Equity (ROE)	14.03%	-29.04%	-16.86%	-179.84%	-	-	Upgrade
Return on Assets (ROA)	-5.32%	-7.21%	-6.78%	-10.07%	-35.20%	-42.38%	Upgrade
Return on Capital (ROIC)	-8.08%	-10.88%	-8.87%	-11.99%	-42.23%	-56.44%	Upgrade
Return on Capital Employed (ROCE)	-8.70%	-13.20%	-15.00%	-13.70%	-75.10%	-86.10%	Upgrade
Earnings Yield	3.04%	-12.19%	-9.86%	115.58%	-24.49%	-24.45%	Upgrade
FCF Yield	25.26%	-2.56%	-5.27%	-24.86%	-25.94%	-22.61%	Upgrade
Buyback Yield / Dilution	-3.49%	11.67%	24.85%	-5.95%	-11.41%	-12.11%	Upgrade

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q